about
Therapeutic drug monitoring of antiretrovirals for people with HIVTherapeutic drug monitoring of antiretrovirals for people with HIVN-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocolSystematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reactionPopulation pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections.Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.The impact of the National HIV Health Care Worker Hotline on patient care in South Africa.Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey.First-line antiretroviral drug discontinuations in childrenInterrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system.Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of ReportsRisk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review.Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa.Antiretroviral therapy and early mortality in South AfricaCases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa.Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switchEffectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.Management of individuals requiring antiretroviral therapy and TB treatment.Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?Provision of antiretroviral therapy in South Africa: the nuts and bolts.Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children.Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy.Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy.Clinician compliance with laboratory monitoring and prescribing guidelines in HIV-1-infected patients receiving tenofovir.A Randomized Controlled Trial of Real-Time Electronic Adherence Monitoring With Text Message Dosing Reminders in People Starting First-Line Antiretroviral Therapy.A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa.Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia.Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis.Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations.NeuroAIDS in children.
P50
Q24239932-F4F24BE9-BDBD-4712-9D98-575A3AC19E98Q24242736-41A1C14A-FE03-4232-8B1F-D1BD084BEB34Q27014948-6268F551-2926-4ACA-A290-D3BABABC0EE8Q28533379-332EC00D-6B34-4EFE-97D9-E461CD80D213Q33364134-D8F11995-BF57-4EA4-B424-A5A3E5279CE2Q33416170-C8C85CF6-5BBE-4DB6-BFBD-DC897C220ABFQ34149022-C2B8519F-78D3-463F-89DE-37B9804FBF1EQ34536677-4A9FA817-5C5A-4470-85C7-8B5372A88C25Q34573636-CA026CB6-E9D2-4491-BF59-CE009E81EE7FQ35132410-D21C325D-9F01-469E-88F9-C58572D982F0Q35598594-AD66903E-FD0B-4F9D-8710-134F1618B25BQ35859876-E9D4419E-97A9-4982-A72C-5BAEE7BFC927Q35906361-344A5538-19D0-4C19-90D7-D5971098E874Q36125525-9FF66C21-6AE3-4280-9832-ECF44DF27A7BQ36278763-5B03A49A-4E3E-4BAE-AF5D-DEBBDEF8CAD5Q36289922-AD1C471C-FD02-46BB-AB9E-D5A09E802881Q36535205-4C26455B-F76D-4E98-BD0F-DC59BFA25DCFQ36663879-78FACE5D-E8F0-4393-9D9D-BF76054AB1BCQ36924709-0BCB826A-B392-4679-ABD7-08EF2021295CQ36993353-215C32D0-374F-4D3D-9E6C-32CD994BCD8CQ37113094-A5DE188A-641B-467F-BC40-A71156366775Q37417023-746EA2CE-D8CC-41A1-A7B9-7ACAE5EC2AF8Q37582314-D18E21AA-C213-41E1-AA8E-AFE7AB869AE8Q37662063-8263AE9A-D63F-44F5-86FD-410AEFF183D2Q37666456-EBB833EE-80B8-4D80-BECF-A2797A9C6B64Q37736861-09B5D7E4-5E91-4C3E-9929-93283AE568F9Q38259626-261BA731-D6F4-4960-8298-7F656A1F3278Q39553824-7F7C340E-ECD2-4CC5-9D7C-E66D5DD4C83BQ40442294-FF284F40-6E0D-4E29-BA7A-53F0E00CB069Q40636440-1555E143-CDEC-4A54-B1BC-ED0EE285905AQ40664342-EB7CD1FE-65E3-4C6C-92B6-35F7E054F9C0Q40733682-1C253F88-E16C-4D4D-9615-2F0FBBC54F76Q41086212-EB200D98-678A-4412-B81B-9917A5355600Q41926207-EC4E049F-168A-4B87-98EB-6D9F51DCB1EFQ42011164-0F34071D-B5F3-4847-9353-954ACDB55DA2Q46447967-12A6F536-A56B-4AF8-A498-3A2563F79919Q46695614-D15822EF-F316-4375-AE54-4A2306FDDEEFQ46838565-D3D41C1D-D725-4941-B41D-E7A1397DF30CQ47579656-4C74274B-AAE8-4FF4-96D2-5C5F7C9DFF85Q52335703-1D638A5A-57B3-4F73-8F3F-557DD35D4D9A
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Karen Cohen
@ast
Karen Cohen
@en
Karen Cohen
@es
Karen Cohen
@nl
Karen Cohen
@sl
type
label
Karen Cohen
@ast
Karen Cohen
@en
Karen Cohen
@es
Karen Cohen
@nl
Karen Cohen
@sl
prefLabel
Karen Cohen
@ast
Karen Cohen
@en
Karen Cohen
@es
Karen Cohen
@nl
Karen Cohen
@sl
P106
P1153
7102615263
P21
P31
P496
0000-0002-1892-4207